BIOLASE, Inc., a medical device company, develops, manufactures, markets, and sells laser systems in dentistry and medicine for patients and health care professionals in the United States and internationally. The company offers Waterlase all-tissue dental laser systems for cutting soft and hard tissues; and diode laser systems, which are used to perform soft tissue, pain therapy, and cosmetic procedures, including teeth whitening. Its dental laser systems allow dentists, periodontists, endodontists, oral surgeons, and other dental specialists to perform a range of dental procedures, such as cosmetic, restorative, and complex surgical applications. The company also markets, sells, and distributes dental imaging equipment, including three-dimensional (3D) CAD/CAM intra-oral scanners and digital dentistry software. Its dental imaging products comprise 3Shape Trios intraoral scanners, digital impression systems, and software for taking 3D scans, which are used to design crowns, study models, surgical guides for implant placement, and event orthodontic and athletic appliances. In addition, the company manufactures and sells consumable products and accessories for its laser systems, as well as markets flexible fibers and hand pieces. It sells its products primarily to dentists in general practice through its field sales force and distributor network. BIOLASE, Inc. was founded in 1984 and is headquartered in Irvine, California.
Industry, Sector and Symbol
Stock Exchange NASDAQ
Industry Dental equipment & supplies
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:BIOL
CUSIPN/A
Phone949-361-1200
Debt
Debt-to-Equity RatioN/A
Current Ratio1.98
Quick Ratio1.03
Price-To-Earnings
Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A
Sales & Book Value
Annual Sales$46.93 million
Price / Sales0.90
Cash FlowN/A
Price / CashN/A
Book Value$1.43 per share
Price / Book1.43
Profitability
EPS (Most Recent Fiscal Year)N/A
Net Income$-16,850,000.00
Net Margins-40.31%
Return on Equity-72.43%
Return on Assets-44.35%
Miscellaneous
Employees195
Outstanding Shares20,600,000
Market Cap$42.84 million
BIOLASE (NASDAQ:BIOL) Frequently Asked Questions
What is BIOLASE's stock symbol?
BIOLASE trades on the NASDAQ under the ticker symbol "BIOL."
When did BIOLASE's stock split? How did BIOLASE's stock split work?
BIOLASE shares reverse split on Friday, May 11th 2018. The 1-5 reverse split was announced on Thursday, May 10th 2018. The number of shares owned by shareholders was adjusted after the market closes on Thursday, May 10th 2018. An investor that had 100 shares of BIOLASE stock prior to the reverse split would have 20 shares after the split.
How were BIOLASE's earnings last quarter?
BIOLASE Inc (NASDAQ:BIOL) released its earnings results on Thursday, August, 9th. The medical technology company reported ($0.20) earnings per share (EPS) for the quarter, meeting the consensus estimate of ($0.20). The medical technology company earned $12.15 million during the quarter. BIOLASE had a negative net margin of 40.31% and a negative return on equity of 72.43%. View BIOLASE's Earnings History.
When is BIOLASE's next earnings date?
Who are some of BIOLASE's key competitors?
Who are BIOLASE's key executives?
BIOLASE's management team includes the folowing people:
- Mr. Todd A. Norbe, Pres, CEO & Director (Age 51)
- Mr. John R. Beaver, Exec. VP & CFO (Age 57)
- Mr. Richard R. Whipp, VP of Operations (Age 66)
- Mr. William E. Brown Jr., VP of Bus. Devel. (Age 70)
- Mr. Daniel Merkin, National Sales Director (Age 45)
Has BIOLASE been receiving favorable news coverage?
Media stories about BIOL stock have trended somewhat positive recently, according to Accern Sentiment. Accern identifies negative and positive press coverage by reviewing more than 20 million blog and news sources. Accern ranks coverage of public companies on a scale of negative one to one, with scores closest to one being the most favorable. BIOLASE earned a news and rumor sentiment score of 0.18 on Accern's scale. They also gave headlines about the medical technology company an impact score of 46.57 out of 100, meaning that recent press coverage is somewhat unlikely to have an impact on the company's share price in the near term. View Recent Headlines for BIOLASE.
Who are BIOLASE's major shareholders?
BIOLASE's stock is owned by many different of institutional and retail investors. Top institutional investors include BlackRock Inc. (1.41%) and Birchview Capital LP (0.66%). Company insiders that own BIOLASE stock include John R Beaver, Jonathan T Md Lord and Larry N Feinberg. View Institutional Ownership Trends for BIOLASE.
Which institutional investors are selling BIOLASE stock?
How do I buy shares of BIOLASE?
Shares of BIOL can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is BIOLASE's stock price today?
One share of BIOL stock can currently be purchased for approximately $2.05.
How big of a company is BIOLASE?
BIOLASE has a market capitalization of $42.84 million and generates $46.93 million in revenue each year. BIOLASE employs 195 workers across the globe.
How can I contact BIOLASE?
BIOLASE's mailing address is 4 CROMWELL, IRVINE CA, 92618. The medical technology company can be reached via phone at 949-361-1200 or via email at [email protected]
MarketBeat Community Rating for BIOLASE (NASDAQ BIOL)
MarketBeat's community ratings are surveys of what our community members think about BIOLASE and other stocks. Vote "Outperform" if you believe BIOL will outperform the S&P 500 over the long term. Vote "Underperform" if you believe BIOL will underperform the S&P 500 over the long term. You may vote once every thirty days.
